Abstract 1447P
Background
Metastatic esophageal squamous cell carcinoma (mESCC) patients with disease progression after platinum-based first-line chemotherapy (CT) +/- radiation +/- immune checkpoint inhibitors (ICI) may benefit from a second-line CT mostly based on paclitaxel and irinotecan but no randomized trial compared these regimens.
Methods
OESIRI-PRODIGE 62 is a multicenter, open-label, randomized phase II trial evaluating efficacy and safety of nanoliposomal irinotecan (Nal-IRI) + 5FU versus paclitaxel as second-line CT in mESCC. The primary endpoint was percentage of pts alive at 9 months (OS) (H0=40% and H1=60%). With α 5%, power 85% and 5% of pts lost to follow-up, 53 pts per arm (n=106) were required. Secondary endpoints were progression-free survival (PFS), overall response rate (ORR), safety and quality of life (QoL).
Results
Between March 2019 and July 2023, 106 pts were randomized. Median age was 65.6 years, 83.0% men and 29.2%/58.5%/12.3% ECOG PS 0/1/2. Most pts had lymph node (68.3%), lung (52.9%) and liver metastases (24.8%). As prior treatment, 48.6% had chemoradiation, 41.9% CT alone and 9.5% CT plus ICI. The OS rate at 9 months was 34.0% [90%CI: 22.9-46.5] and 39.2% [90%CI: 27.7-51.7] in 5FU Nal-IRI and paclitaxel arms, respectively. Primary endpoint was not met. Median PFS were 2.4 [95%CI: 2.1-3.6] and 2.1 [95%CI: 1.9-3.3] months, disease control rates 47.8% and 40.4%, and median OS 7.1 [95%CI: 5.2-8.3] and 6.6 [95%CI: 4.8-10.3] months, respectively. 51.0% and 38.5% of pts experienced at least one grade 3-4 adverse events related to the treatment (neuropathy: 2.0 vs 7.7%, leucopenia: 6.1 vs 15.4%, diarrhea: 16.3% vs 0% and vomiting: 10.2 vs 0%), in 5FU Nal-IRI and paclitaxel arms, respectively. Two toxic deaths were observed in 5FU Nal-IRI arm. Treatment stop and dose reduction for toxicity were observed in 10.4% versus 3.9%, and 77.8% versus 83.3% in 5FU Nal-IRI and paclitaxel arms, respectively. 63.0% and 48.3% had a deterioration in QoL (loss of more than 5 points of the EORTC-QLQC30).
Conclusions
OESIRI-PRODIGE 62 trial showed low efficacy of paclitaxel and 5FU Nal-IRI in 2nd line treatment for mESCC patients, though paclitaxel provided better safety profile.
Clinical trial identification
NCT03719924.
Editorial acknowledgement
Legal entity responsible for the study
Fédération Francophone de Cancérologie Digestive.
Funding
Servier.
Disclosure
D. Tougeron: Financial Interests, Personal, Advisory Board: AstraZeneca, Sanofi, Amgen, MSD, Roche, Servier, Pierre Fabre, BMS, Bayer; Non-Financial Interests, Member of Board of Directors: Federation Francophone de Cancerologie Digestive. C. Poisson Ligeza: Financial Interests, Personal, Invited Speaker: Servier. V. Bourgeois: Financial Interests, Personal, Advisory Board: Servier; Financial Interests, Personal, Principal Investigator: AstraZeneca; Non-Financial Interests, Personal, Non financial benefits, Congress Invitation: Merck, Amgen, Viatris, Pierre Fabre, MSD. V. Jestin: Financial Interests, Personal, Other, invitation à une formation: Novartis, MSD, Merck; Financial Interests, Personal, Other, contribution organisation réunion scientifique: Leopharma; Financial Interests, Personal, Invited Speaker: Sanofi. O. Dubreuil: Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Invited Speaker: Sanofi, Pierre Fabre, Servier, MSD, AstraZeneca. O. Bouche: Financial Interests, Personal, Advisory Board: Amgen, Merck, Apmonia Therapeutics, Deciphera, Astellas, Takeda; Financial Interests, Personal, Invited Speaker: Servier, Pierre Fabre, Bayer. A. Lievre: Financial Interests, Personal, Invited Speaker: Amgen, Astellas, AstraZeneca, BMS, Esteve, Pierre Fabre Oncologie, Servier, Viatris; Financial Interests, Personal, Advisory Board: Astellas, BMS, Bayer, Servier; Financial Interests, Institutional, Research Grant, RePERSO trial: Bayer; Financial Interests, Institutional, Coordinating PI, SOCRATE trial (FFCD promotion): Lilly; Non-Financial Interests, Principal Investigator: AstraZeneca, BMS, Bayer, Incyte, Lilly; Non-Financial Interests, Other, Travel and meeting registration: Bayer, Pierre Fabre, Servier, Viatris. F. Di Fiore: Financial Interests, Personal, Advisory Board: Amgen, BMS; Financial Interests, Personal, Invited Speaker: AstraZeneca, Sanofi, Bayer, Ipsen, Merck, Roche, Servier, MSD, Pierre Fabre, Takeda, Janssen. T. Lecomte: Financial Interests, Personal, Advisory Board: Sanofi, Merck Serono, Servier, Amgen, Ipsen, Pierre Fabre, AstraZeneca, Deciphera, Bayer. C. Lepage: Financial Interests, Personal, Advisory Board: AAA; Financial Interests, Personal, Invited Speaker: Amgen, Pierre Fabre, Ipsen. V. Hautefeuille: Financial Interests, Personal, Invited Speaker: Novartis, Merck, Amgen; Financial Interests, Personal, Advisory Board: AAA, Ipsen, Pierre Fabre; Financial Interests, Institutional, Invited Speaker: Deciphera, Esteve. All other authors have declared no conflicts of interest.
Resources from the same session
1525P - Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Presenter: Jens Siveke
Session: Poster session 18
1527P - GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
Presenter: Satoshi Kobayashi
Session: Poster session 18
1528P - TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
Presenter: Yung-yeh Su
Session: Poster session 18
1531TiP - TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC
Presenter: Michael Overman
Session: Poster session 18
1532TiP - Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
Presenter: Wungki Park
Session: Poster session 18
1533TiP - A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Presenter: Xiaofei Zhang
Session: Poster session 18
1534TiP - Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial
Presenter: Alfredo Budillon
Session: Poster session 18